Form D · Pharmaceuticals

Neumentum, Inc.

Summit, NJ · CIK 0001720959

Offering snapshot reported Apr 28, 2023 · SEC filing

Reported sold
$16.6M
Offering amount: $20M
Investors reported
33
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 30, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$8.28M$16.6MOct 14, 2021: $13,300,000.00Oct 14, 2021Oct 21, 2021: $13,300,000.00Apr 28, 2023: $16,559,757.00Apr 28, 2023

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$13,300,000 → $16,559,757
  • Reported investors28 → 33

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 28, 2023Amendment$16,559,757$3,259,757vs Oct 14, 202133SEC filing
Oct 21, 2021Amendment$13,300,000$0vs Oct 14, 202128SEC filing
Oct 14, 2021Initial$13,300,000No comparison28SEC filing
Nov 15, 2019Initial$2,663,000No comparison18SEC filing
Sep 6, 2019Amendment$3,020,000$1,970,000vs Mar 27, 201936SEC filing
Mar 27, 2019Initial$1,050,000No comparison9SEC filing
May 25, 2018Initial$5,000,000No comparison38SEC filing
Oct 31, 2017Initial$5,260,000No comparison53SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$300K (estimated)
Finders' fees
$0
Form D file number
021-416963
Commissions are a percentage of total offering; $300,000 estimate calculated assuming $5mm raised during 2023 offering period. Agent shall also receive a 7 year warrant to purchase up to 237,290 shares of common stock at an exercise price of $1.6225/share

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Brookline Capital Markets, a division of Arcadia Securities, LLC44656

Source: Form D, filed Apr 28, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andrew Blank Director
Christine Cvijic Director, Executive
Pedro Granadillo Director
Taggart Mc Gurrin Executive
August Moretti Director
Joseph Pergolizzi Director
Richard Scott Shively Director, Executive
Ilona Steigerwald Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
350 Springfield Avenue Suite 200
Summit, NJ, 07901